Posos’ Post

We are pleased to announce the recently concluded Phase 2 collaboration between Codix Pharma Ltd and the Medical Laboratory Science Council of Nigeria on capacity building for the MLSCN IVD staff. Our commitment to advancing healthcare extends beyond the solutions we offer and patient care, it is about fostering support and building capacity for healthcare professionals. Recognizing the pivotal role of these healthcare professionals within the value chain in terms of timely and effective diagnosis. The Codix Academy initiative endeavours to empower stakeholders within the healthcare system with the knowledge and resources necessary to improve diagnosis, patient management, and care. At Codix, we strive to promote technological innovation within the healthcare landscape, as reflected in our contributions in the industry by advancing localized solutions and contributing to the development of the Nigerian healthcare sector. #Stakeholderengagement #Socialresponsibility #Codix

The topic for this week’s The Kinetix Group-Powered by Petauri™ PACT Executive Briefing is, “Pharmacist Collaborative Practice Agreements (CPAs).” All 50 states now allow pharmacists and physicians to enter into Collaborative Practice Agreements (CPAs) in which one or more pharmacists establish a formal relationship with a prescriber, in which the prescriber can delegate specific tasks to a pharmacist under negotiated conditions, which would not otherwise be permitted under the pharmacist’s normal scope of practice Although state laws vary, generally, CPAs allow prescribers to delegate specific patient care tasks to pharmacists. The pharmacist’s scope of practice under a CPA is generally defined by established protocols that are condition or disease specific. For example, under a CPA, pharmacists may be empowered to perform patient assessments, order laboratory tests, prescribe drugs, counsel patients, and make referrals for related care. They may also be permitted to select, initiate, monitor, continue, discontinue, adjust, and refill ongoing therapy regimens. Expanding a pharmacist’s traditional scope of practice through CPAs may open up unique opportunities for life science companies to improve access to therapy, address health equity concerns, and allow for better care coordination among multiple care providers and in complex patient situations. Check out The Kinetix Group-Powered by Petauri™ growing library of TKG PACT Executive Briefings where you can listen and download the companion PDF infographics. https://lnkd.in/evZKhgre #Market_Access, #TKG, #TKGPACT, #Pharmacist_CPA, #Collaborative_Practice_Agreement, #Pharmacist, #Specialty_Pharmacy, #Pharmacy, #Medication

The most needed topic nowadays. Practically, I think AI can assist in pharmacovigalance by automating adverse event detection, medical assessment of ICSRs, analyzing large-scale data for signal detection, supporting risk assessment, and enhancing the efficiency and accuracy of adverse event analysis. #ArtificialIntelligence #Pharmcovigilance

#Clinicaltrial specimen collection comes with its challenges, from insufficient specimens to labelling, tracking and timeline pressures. This is why RDi ensures all its products and services are compatible with the needs of this sector. We offer bulk supply and delivery of kits and packaging products, which can be pre-labelled with subject or patient details for phase I, II and III trials. We’ve delivered over 100 million kits to date, with our products integrating with study participant data to streamline specimen collection. Built in compliance accelerates the testing and transport of clinical trial samples to expedite the discovery and qualification of new treatments! Partner with RDi to transform your clinical trials: https://bit.ly/3zpK7gz #drugdevelopement #clinicalresearch #clinicaltrial

From small initial volumes to full national supply RDi will ensure scalability and be with you at every step of the process ensuring clear communication and transparency.

Calling all pharmacy innovators and researchers! 🚀 A special issue in Pharmacy MDPI journal 'Medication Safety and Pharmacy Practice' edited by Dr. Kevin T. Fuji is open for submission! Join us in shaping the future of pharmacy by submitting your latest research, reviews, or perspectives to this special issue. Let's collaborate to drive advancements in medication safety and optimize patient care outcomes. 🌟 Submit your manuscript today and be part of the solution! 📝 #Pharmacy #MedicationSafety #PharmacyPractice #ResearchOpportunity Check it out on the following link: https://lnkd.in/ddbeprNG

🎉 We are thrilled to announce Dr. Deborah Jones, Ph.D, EMEIA Sales Director at Proveris Scientific Corporation, is an Official Speaking Partner at the 5th Annual Inhalation and Respiratory Drug Delivery Conference in Berlin, Germany, from September 18-20, 2024. 📍 Join Deborah at Eurostars Berlin Luxury Class Hotel for insightful discussions on inhalation and nasal drug delivery testing solutions. PRESENTATION OVERVIEW Derisking OINDP Development: Incorporating nasal sprays, PMDIs, SMIs, and DPIs 🔹Understand the multifaceted interactions between patient, formulation, and device in OINDP development. 🔹Explore the unique development challenges of each drug type. 🔹Learn how to utilize knowledge and tools to gain insights and mitigate risks in product development. 📨 Connect in advance of the conference: djones@proveris.com 🌐 Visit the conference website: https://lnkd.in/dkTgGQFU #Proveris #Instruments #LaboratoryTestServices #OINDP #InhalerTesting #NasalSprayTesting #DrugDevelopment

  atai Life Sciences (NASDAQ:ATAI, ETR:9VC) co-founder and co-CEO Dr Srinivas Rao takes Proactive's Stephen Gunnion through the positive results from the Phase 1b trial for VLS-01, emphasizing its excellent tolerability and potential as a best-in-class treatment option. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. VLS-01 is being developed for treatment-resistant depression, a condition that impacts the lives of an estimated 100 million people globally. Srinivas emphasizes the potential of VLS-01 as a best-in-class treatment option, with excellent tolerability, patient-friendly administration and a short 2-hour in-clinic treatment time. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. Rao... Watch at #Proactive #ProactiveInvestors http://ow.ly/3fqe105Fnmb

IRT plays a critical role in #clinicaltrials, whether in the randomization of subjects or supporting the supply and management of investigational drugs across multi-regional clincal trials. These processes face numerous risks and challenges, including regulatory compliance, cultural differences, and varying social environments. Effectively addressing these issues is crucial. Join us for an exclusive webinar with SHANHU director of clinical technology,Bright Chen, on "Global Regulatory Perspectives on IRT in Multi-regional Clinical Trials(#MRCT)." Learn the latest #regulations and practical experiment in MRCT projects. link：https://lnkd.in/guCtuKHJ